Moderna (MRNA) to Release Earnings on Thursday

Moderna (NASDAQ:MRNA) will be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Moderna to post earnings of ($3.36) per share for the quarter. Moderna has set its FY 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. During the same period in the previous year, the firm earned $3.61 EPS. The firm’s revenue was down 44.9% compared to the same quarter last year. On average, analysts expect Moderna to post $-8 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Moderna Stock Up 0.9 %

NASDAQ MRNA opened at $108.85 on Thursday. The stock’s 50 day moving average is $101.85 and its 200 day moving average is $93.64. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. Moderna has a 12 month low of $62.55 and a 12 month high of $142.79. The stock has a market cap of $41.68 billion, a PE ratio of -8.77 and a beta of 1.62.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 647 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Moderna news, CFO James M. Mock sold 647 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders have sold 109,954 shares of company stock valued at $11,533,976 in the last quarter. 15.20% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. HSBC reaffirmed a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research note on Tuesday, January 2nd. Finally, William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.